Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen

Rallybio (NASDAQ:RLYB) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Rallybio currently has an average rating of “Reduce”.

Rallybio Price Performance

Shares of NASDAQ:RLYB opened at $8.22 on Friday. The business’s fifty day moving average price is $6.97 and its two-hundred day moving average price is $5.76. Rallybio has a fifty-two week low of $1.76 and a fifty-two week high of $11.49. The stock has a market capitalization of $43.48 million, a price-to-earnings ratio of -3.21 and a beta of -1.13.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.10 million. Research analysts expect that Rallybio will post -1.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Rallybio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RLYB. XTX Topco Ltd raised its stake in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares during the last quarter. Susquehanna International Group LLP increased its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares in the last quarter. Finally, Citadel Advisors LLC raised its position in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.